Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, announced participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, announced participation in two investor conferences. CEO Mark A. Goldsmith will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 1:10 to 1:40 p.m. Eastern. Additionally, he will participate in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum on March 29, 2021, from 2:00 to 2:45 p.m. Eastern. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, with R&D initiatives around RAS(ON) and Companion Inhibitors.
Details
News Market Reaction – RVMD
The recorded move for RVMD in the trading session of this news was +5.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will deliver a corporate presentation at the Oppenheimer 31st Annual Healthcare Conference and be the featured speaker in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum.
Details of these events are as follows:
- Oppenheimer 31st Annual Healthcare Conference
Conference Date: March 16-18, 2021
Presentation Time/Date: 1:10 – 1:40 p.m. Eastern on Tuesday, March 16, 2021
Format: Virtual conference
- J.P. Morgan 10th Annual Napa Valley Forum
Conference Date: March 29-31, 2021
Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021
Format: Virtual conference
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.